AstraZeneca PLC said Thursday that Phase 3 trials on its AZD7442 antibody combination confirmed that the treatment reduces risk of developing symptomatic Covid-19.
The pharmaceutical company
said the analysis of its continuing trial evaluating a median six months of participant follow-up revealed that one dose of AZD7442 showed 83% reduced symptomatic Covid-19 risk and no severe disease or deaths.
A separate trial in patients with mild-to-moderate Covid-19 showed that a larger dose of AZD7442 reduced risk of severe Covid-19 or death by 88% compared to placebo, in patients who had been symptomatic for three days or fewer at the time of the treatment.
“These compelling results give me confidence that this long-acting antibody combination can provide my vulnerable patients with the long-lasting protection they urgently need to finally return to their everyday lives,” Hugh Montgomery, a professor at University College London and AZD7442 principal investigator, said.
Write to Jaime Llinares Taboada at firstname.lastname@example.org; @JaimeLlinaresT